EE9800105A - Dendriitrakke stimuleeriv faktor - Google Patents

Dendriitrakke stimuleeriv faktor

Info

Publication number: EE9800105A
Authority: EE; Estonia
Prior art keywords: stimulating factor; dendritic cell; cell stimulating; dendritic cells; cells
Prior art date: 1995-10-04

Application number

EE9800105A

Other languages

English (en)

Estonian (et)

Inventor

D. Lyman Stewart

R. Mckenna Hilary

H. Lynch David

Brasel Kenneth

Maraskovsky Eugene

Original Assignee

Immunex Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-10-04

Filing date

1996-10-03

Publication date

1998-10-15

1996-10-03 Application filed by Immunex Corporation filed Critical Immunex Corporation

1998-10-15 Publication of EE9800105A publication Critical patent/EE9800105A/xx

Links

210000004443 dendritic cell Anatomy 0.000 title abstract 4
230000004936 stimulating effect Effects 0.000 title 1
102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 abstract 2
101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 1
210000001744 T-lymphocyte Anatomy 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
210000003958 hematopoietic stem cell Anatomy 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
210000000130 stem cell Anatomy 0.000 abstract 1
239000012646 vaccine adjuvant Substances 0.000 abstract 1
229940124931 vaccine adjuvant Drugs 0.000 abstract 1
230000003612 virological effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Biotechnology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Hematology (AREA)
Cell Biology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
AIDS & HIV (AREA)
Mycology (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Tropical Medicine & Parasitology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EE9800105A 1995-10-04 1996-10-03 Dendriitrakke stimuleeriv faktor EE9800105A (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US53914295A	1995-10-04	1995-10-04
PCT/US1996/015990 WO1997012633A1 (en)	1995-10-04	1996-10-03	Dendritic cell stimulatory factor

Publications (1)

Publication Number	Publication Date
EE9800105A true EE9800105A (et)	1998-10-15

Family

ID=24149974

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EE9800105A EE9800105A (et)	1995-10-04	1996-10-03	Dendriitrakke stimuleeriv faktor

Country Status (23)

Country	Link
EP (1)	EP0871487B1 (cs)
JP (1)	JP3631496B2 (cs)
KR (2)	KR100514957B1 (cs)
CN (1)	CN1172718C (cs)
AT (1)	ATE432085T1 (cs)
AU (1)	AU697539B2 (cs)
BR (1)	BR9610802A (cs)
CA (1)	CA2232865A1 (cs)
CZ (1)	CZ97798A3 (cs)
DE (1)	DE69637942D1 (cs)
EA (1)	EA199800272A1 (cs)
EE (1)	EE9800105A (cs)
ES (1)	ES2323818T3 (cs)
IS (1)	IS4703A (cs)
LV (1)	LV12085B (cs)
NO (1)	NO981374L (cs)
NZ (1)	NZ321039A (cs)
PL (1)	PL187329B1 (cs)
RO (1)	RO120579B1 (cs)
SI (1)	SI9620116A (cs)
SK (1)	SK40898A3 (cs)
TR (1)	TR199800607T1 (cs)
WO (1)	WO1997012633A1 (cs)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6429199B1 (en)	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
US20030026782A1 (en)	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US9068164B1 (en) *	1995-02-02	2015-06-30	Tristem Trading (Cyprus) Limited	Method of preparing an undifferentiated cell
EP0961824A4 (en) *	1996-07-10	2003-01-29	Immunex Corp	METHOD FOR ACTIVATING DENTRITIC CELLS
AUPO388396A0 (en) *	1996-11-27	1996-12-19	Ludwig Institute For Cancer Research	Cellular adjuvant
AU7835898A (en) *	1997-06-17	1999-01-04	Immunex Corporation	A method of enhancing antigen-specific peripheral immune tolerance
FR2782524B1 (fr) *	1998-08-21	2002-07-19	Roussy Inst Gustave	Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre
FR2775692B1 (fr) *	1998-03-03	2000-06-16	Roussy Inst Gustave	Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre
US6849452B1 (en) *	1998-03-03	2005-02-01	Institut Gustave Roussy	Methods for activating natural killer (NK) cells and means for carrying out said methods
SI1077722T1 (sl)	1998-05-22	2007-02-28	Ottawa Health Research Inst	Metode in produkti za induciranje sluznicne imunosti
WO1999062537A1 (en) *	1998-06-04	1999-12-09	The Rockefeller University	Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins
US6291661B1 (en)	1998-07-02	2001-09-18	Immunex Corporation	flt3-L mutants and method of use
AU5741699A (en)	1998-08-27	2000-03-21	Universitatsklinikum Freiburg	Low-molecular fragments of hyaluronic acid for the preparation of vaccines
GB9827604D0 (en) *	1998-12-15	1999-02-10	Lorantis Ltd	Methods of immunosuppression
WO2001009303A2 (en) *	1999-07-30	2001-02-08	Vical Inc.	Flt-3 LIGAND-ENCODING POLYNUCLEOTIDE AS A POLYNUCLEOTIDE-BASED VACCINE ENHANCER
JP2004522403A (ja) *	1999-11-03	2004-07-29	パウダージェクトヴァクシンズ，インコーポレイテッド	抗原発現を駆動する哺乳動物ｃｄ８０／ｃｄ８６遺伝子プロモーターを有する核酸ワクチン組成物
JP2003523398A (ja) *	2000-02-24	2003-08-05	ザボードオブトラスティーズオブザリーランドスタンフォードジュニアユニバーシティ	樹状細胞のインビボ活性化によるアジュバント治療
US7572631B2 (en)	2000-02-24	2009-08-11	Invitrogen Corporation	Activation and expansion of T cells
US7541184B2 (en)	2000-02-24	2009-06-02	Invitrogen Corporation	Activation and expansion of cells
ES2254408T4 (es) *	2000-04-25	2007-10-01	Immunex Corporation	Procedimiento de tratamiento de tumores usando terapia fotodinamica.
AU2002232447A1 (en) *	2000-11-02	2002-05-15	Immunex Corporation	Method of enhancing lymphocyte-mediated immune responses
AU2002225927A1 (en) *	2000-11-17	2002-05-27	Immunex Corporation	Chemoattractant recruitment of dendritic cells for enhancement of immunization
CA2459713C (en) *	2001-09-06	2015-08-18	Northwest Biotherapeutics, Inc.	Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response
KR100490308B1 (ko) *	2002-02-25	2005-05-17	크레아젠 주식회사	면역 치료용 성숙화된 수지상 세포 백신의 제조방법
MXPA04009394A (es) *	2002-03-26	2005-01-25	Inmunex Corp	Metodos para utilizar ligando flt3 en procedimientos de inmunizacion.
US20050084967A1 (en)	2002-06-28	2005-04-21	Xcyte Therapies, Inc.	Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
KR100522526B1 (ko) *	2002-11-28	2005-10-19	주식회사 바이넥스	면역 치료용 수지상 세포의 제조방법
KR100614220B1 (ko) *	2004-11-08	2006-08-21	고려대학교 산학협력단	Ｆｌｔ3 리간드 유전자를 발현하는 살모넬라 균주 및 이를함유하는 항암 치료용 조성물
DE102005016234B4 (de) *	2005-04-08	2008-05-15	Tgc Biomics Gmbh	Verfahren zur Einschleusung von exogenem Antigen in den MHC I-Präsentationsweg von Zellen
KR100818215B1 (ko)	2006-10-11	2008-04-01	재단법인서울대학교산학협력재단	Ｃｄ３４양성 줄기세포로부터 ｔ 임파구 전구체를 제조하는 방법
KR101264811B1 (ko)	2011-05-20	2013-05-15	충남대학교산학협력단	마이코박테리움 압세수스의 ＭＡＢ０９８１ｃ 단백질을 이용한 수지상 세포의 성숙방법
CN109563481B (zh)	2016-07-13	2024-01-05	俄亥俄州创新基金会	用于优化宿主抗原呈递和宿主抗肿瘤和抗病原体免疫的平台和方法
SG11202104352XA (en)	2018-12-18	2021-05-28	Boehringer Ingelheim Io Canada Inc	Flt3 agonist antibodies and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US826250A (en)	1905-12-20	1906-07-17	Albert Huck	Switch for toy railways.
US4714680B1 (en)	1984-02-06	1995-06-27	Univ Johns Hopkins	Human stem cells
US5391485A (en)	1985-08-06	1995-02-21	Immunex Corporation	DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
EP0790307A1 (en)	1986-12-16	1997-08-20	Gist-Brocades B.V.	Molecular cloning and expression of human IL-3
OA09736A (en)	1987-02-18	1993-11-30	Schering Biotech Corp	"Human interleukin-3 and muteins thereof".
JPH03502322A (ja)	1987-10-30	1991-05-30	イミュネックス・コーポレーション	ヒトコロニー形成刺激因子の非グリコシル化類似体
US5108910A (en)	1989-08-22	1992-04-28	Immunex Corporation	DNA sequences encoding fusion proteins comprising GM-CSF and IL-3
US5073627A (en)	1989-08-22	1991-12-17	Immunex Corporation	Fusion proteins comprising GM-CSF and IL-3
DK0423980T3 (da)	1989-10-16	2000-10-09	Amgen Inc	Stamcellefaktor
US5199942A (en)	1991-06-07	1993-04-06	Immunex Corporation	Method for improving autologous transplantation
ES2180539T3 (es)	1991-10-23	2003-02-16	Nexell Therapeutics Inc	Metodos para expandir selectivamente celulas madre.
US5554512A (en)	1993-05-24	1996-09-10	Immunex Corporation	Ligands for flt3 receptors
CZ307995A3 (en) *	1993-05-24	1996-10-16	Immunex Corp	Ligands for flt3 receptors
US5405772A (en)	1993-06-18	1995-04-11	Amgen Inc.	Medium for long-term proliferation and development of cells

1996
- 1996-10-03 RO RO98-00824A patent/RO120579B1/ro unknown
- 1996-10-03 SI SI9620116A patent/SI9620116A/sl unknown
- 1996-10-03 TR TR1998/00607T patent/TR199800607T1/xx unknown
- 1996-10-03 ES ES96936216T patent/ES2323818T3/es not_active Expired - Lifetime
- 1996-10-03 NZ NZ321039A patent/NZ321039A/en unknown
- 1996-10-03 EP EP96936216A patent/EP0871487B1/en not_active Expired - Lifetime
- 1996-10-03 SK SK408-98A patent/SK40898A3/sk unknown
- 1996-10-03 DE DE69637942T patent/DE69637942D1/de not_active Expired - Lifetime
- 1996-10-03 EA EA199800272A patent/EA199800272A1/ru unknown
- 1996-10-03 PL PL96325964A patent/PL187329B1/pl not_active IP Right Cessation
- 1996-10-03 KR KR10-1998-0702286A patent/KR100514957B1/ko not_active Expired - Fee Related
- 1996-10-03 KR KR1020047011434A patent/KR100676792B1/ko not_active Expired - Fee Related
- 1996-10-03 AU AU73922/96A patent/AU697539B2/en not_active Ceased
- 1996-10-03 JP JP51449097A patent/JP3631496B2/ja not_active Expired - Fee Related
- 1996-10-03 EE EE9800105A patent/EE9800105A/xx unknown
- 1996-10-03 WO PCT/US1996/015990 patent/WO1997012633A1/en not_active Ceased
- 1996-10-03 BR BR9610802A patent/BR9610802A/pt unknown
- 1996-10-03 CZ CZ98977A patent/CZ97798A3/cs unknown
- 1996-10-03 CA CA002232865A patent/CA2232865A1/en not_active Abandoned
- 1996-10-03 AT AT96936216T patent/ATE432085T1/de not_active IP Right Cessation
- 1996-10-03 CN CNB96197351XA patent/CN1172718C/zh not_active Expired - Fee Related
1998
- 1998-03-26 NO NO981374A patent/NO981374L/no unknown
- 1998-03-26 IS IS4703A patent/IS4703A/is unknown
- 1998-04-02 LV LVP-98-63A patent/LV12085B/en unknown

Also Published As

Publication number	Publication date
WO1997012633A1 (en)	1997-04-10
CA2232865A1 (en)	1997-04-10
CZ97798A3 (cs)	1999-02-17
LV12085A (lv)	1998-07-20
KR20040079421A (ko)	2004-09-14
JPH11513389A (ja)	1999-11-16
PL325964A1 (en)	1998-08-17
SI9620116A (sl)	1999-08-31
LV12085B (en)	1998-09-20
EP0871487A4 (en)	2004-09-01
AU7392296A (en)	1997-04-28
DE69637942D1 (de)	2009-07-09
ES2323818T3 (es)	2009-07-24
CN1229359A (zh)	1999-09-22
KR19990063818A (ko)	1999-07-26
ATE432085T1 (de)	2009-06-15
NZ321039A (en)	2001-03-30
TR199800607T1 (xx)	1998-06-22
RO120579B1 (ro)	2006-04-28
KR100676792B1 (ko)	2007-02-02
EP0871487A1 (en)	1998-10-21
JP3631496B2 (ja)	2005-03-23
IS4703A (is)	1998-03-26
KR100514957B1 (ko)	2005-11-25
NO981374D0 (no)	1998-03-26
EP0871487B1 (en)	2009-05-27
CN1172718C (zh)	2004-10-27
BR9610802A (pt)	1999-07-13
SK40898A3 (en)	1999-04-13
AU697539B2 (en)	1998-10-08
PL187329B1 (pl)	2004-06-30
NO981374L (no)	1998-06-03
EA199800272A1 (ru)	1998-10-29

Publication	Publication Date	Title
EE9800105A (et)	1998-10-15	Dendriitrakke stimuleeriv faktor
NO986173L (no)	1999-03-10	FremgangsmÕte for aktivering av dendrittceller
IL114444A0 (en)	1995-11-27	Multi-stage cascade boosting vaccine
DK0633929T3 (da)	2004-06-28	Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
DE69418856D1 (de)	1999-07-08	Targeting von immunogenen durch lysosomen
MX9203439A (es)	1992-08-01	Una citocina mamifera, il-11
IL98957A0 (en)	1992-07-15	Immunotherapy with interleukin-7
NZ322910A (en)	2000-05-26	Tumour vaccine containing tumour cells, some with MHC-I-haplotype on cell surface to trigger immune response, and preparation of vaccine thereof
EP2377548A3 (en)	2012-10-10	Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
DE69329344D1 (de)	2000-10-05	Spezifische modulationen des immunsystems
DE69839273D1 (de)	2008-04-30	Krebs immuntherapie mit semi-allogenen zellen
CY1110235T1 (el)	2015-01-14	Χρηση αλλογενετικων κυτταρικων γραμμων για τη φορτωση κυτταρων που εμφανιζουν αντιγονο για την προκληση ή εξαλειψη ανοσολογικων απαντησεων
DK0843731T3 (da)	2008-06-09	Adenovirusvektorer til genterapi
DE50008756D1 (de)	2004-12-30	Peptid aus antigen muc-1 zur auslösung einer immunreaktion gegen tumorzellen
ATE412763T1 (de)	2008-11-15	Antikörper-abhängige vergrösserung der alphavirus-infektvität
DE60130634D1 (de)	2007-11-08	Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden
ATE385809T1 (de)	2008-03-15	Saponin-zusammensetzungen und deren verwendung
Sofra et al.	2009	Antigen‐loaded ER microsomes from APC induce potent immune responses against viral infection
ES2017258A6 (es)	1991-01-16	Un metodo para producir peptidos antigenicos relacionados con el antigeno p97 asociado a melanoma.
DE69835615D1 (de)	2006-09-28	Induzierte zelluläre immunitität durch aktivierung der th1 und unterdrückung der th2 antwort durch macrophhagen
Szostak	1997	Rekombinante Bakteriunhuellen als Impfstoffe.
MX9606317A (es)	1998-01-31	Metodos para la activacion de celulas t in vivo por celulas dentriticas impulsadas por antigenos.
Suciu-Foca et al.	1989	7.1-03 A new differentiation antigen, NDA5, involved in the amplification of primary and memory T cell responses